Panic disorder study
Eligibility criteria
- Male or female ≥ 18 and ≤ 65 years of age
- Experiences recurring, unexpected panic attacks
- Willing to remain on current doses of psychiatric medications throughout the length of the trial
- Must not have concurrent severe agoraphobia y, obsessive-compulsive disorder (OCD), Bipolar disorder, or any other schizoaffective or psychotic disorders
- Must be willing to stop/avoid benzodiazepine use during the trial
Full description
Panic Disorder is an anxiety disorder characterised by repeated and unpredictable panic attacks, involving sudden onset of fear and anxiety. These are attacks are not caused by a known fear or stressor and relate to abnormalities in the central nervous system (CNS).
Current treatment options for panic disorder include serotonin and norepinephrine reuptake inhibitors (SSRIs/SNRIs) and benzodiazepines (BDZs). Currently, there are no specific FDA approved treatments that are designed to specifically target the CNS response. Panic Disorder has a considerable impact on the physical and psychological wellbeing of individuals, and it is critically important new treatments are developed.
This study is investigating the use of a new medication that is a combination of two previously approved treatments for hypertension to target the CNS physiological stress system for patients with panic disorder.
Study Details
The study would require you to come in for 6 site visits, 8 video calls, and one phone call over a 4-month period. Visits will range between 30 mins and 3 hours each time you come in. At visits we will check your medical history, conduct a physical examination, complete a questionnaire regarding your panic attacks, perform an ECG and run some blood tests.
You will be reimbursed for your time and involvement in the research study.